Literature DB >> 25642320

Review of naloxone safety for opioid overdose: practical considerations for new technology and expanded public access.

Daniel P Wermeling1.   

Abstract

Opioid overdose and mortality have increased at an alarming rate prompting new public health initiatives to reduce drug poisoning. One initiative is to expand access to the opioid antidote naloxone. Naloxone has a long history of safe and effective use by organized healthcare systems and providers in the treatment of opioid overdose by paramedics/emergency medicine technicians, emergency medicine physicians and anesthesiologists. The safety of naloxone in a prehospital setting administered by nonhealthcare professionals has not been formally established but will likely parallel medically supervised experiences. Naloxone dose and route of administration can produce variable intensity of potential adverse reactions and opioid withdrawal symptoms: intravenous administration and higher doses produce more adverse events and more severe withdrawal symptoms in those individuals who are opioid dependent. More serious adverse reactions after naloxone administration occur rarely and may be confounded by the effects of other co-intoxicants and the effects of prolonged hypoxia. One component of the new opioid harm reduction initiative is to expand naloxone access to high-risk individuals (addicts, abusers, or patients taking high-dose or extended-release opioids for pain) and their close family or household contacts. Patients or their close contacts receive a naloxone prescription to have the medication on their person or in the home for use during an emergency. Contacts are trained on overdose recognition, rescue breathing and administration of naloxone by intramuscular injection or nasal spraying of the injection prior to the arrival of emergency medical personnel. The safety profile of naloxone in traditional medical use must be considered in this new context of outpatient prescribing, dispensing and treatment of overdose prior to paramedic arrival. New naloxone delivery products are being developed for this prehospital application of naloxone in treatment of opioid overdose and prevention of opioid-induced mortality.

Entities:  

Keywords:  antidote; drug-delivery systems; naloxone; opioid; overdose

Year:  2015        PMID: 25642320      PMCID: PMC4308412          DOI: 10.1177/2042098614564776

Source DB:  PubMed          Journal:  Ther Adv Drug Saf        ISSN: 2042-0986


  40 in total

1.  Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers.

Authors:  Jonathonm Dowling; Geoffrey K Isbister; Carl M J Kirkpatrick; Daya Naidoo; Andis Graudins
Journal:  Ther Drug Monit       Date:  2008-08       Impact factor: 3.681

2.  Efficacy of intranasal naloxone as a needleless alternative for treatment of opioid overdose in the prehospital setting.

Authors:  Erik D Barton; Christopher B Colwell; Timothy Wolfe; Dave Fosnocht; Craig Gravitz; Tamara Bryan; Will Dunn; Jeff Benson; Jeff Bailey
Journal:  J Emerg Med       Date:  2005-10       Impact factor: 1.484

3.  Are heroin overdose deaths related to patient release after prehospital treatment with naloxone?

Authors:  G M Vilke; J Buchanan; J V Dunford; T C Chan
Journal:  Prehosp Emerg Care       Date:  1999 Jul-Sep       Impact factor: 3.077

4.  Intranasal administration of naloxone by paramedics.

Authors:  Erik D Barton; Joseph Ramos; Christopher Colwell; Jeff Benson; Jeff Baily; William Dunn
Journal:  Prehosp Emerg Care       Date:  2002 Jan-Mar       Impact factor: 3.077

5.  Mental illness and psychotropic drug use among prescription drug overdose deaths: a medical examiner chart review.

Authors:  Robin L Toblin; Leonard J Paulozzi; Joseph E Logan; Aron J Hall; James A Kaplan
Journal:  J Clin Psychiatry       Date:  2010-04       Impact factor: 4.384

6.  The relationship between naloxone dose and key patient variables in the treatment of non-fatal heroin overdose in the prehospital setting.

Authors:  Kate Cantwell; Paul Dietze; Louisa Flander
Journal:  Resuscitation       Date:  2005-06       Impact factor: 5.262

7.  Opioid overdose prevention with intranasal naloxone among people who take methadone.

Authors:  Alexander Y Walley; Maya Doe-Simkins; Emily Quinn; Courtney Pierce; Ziming Xuan; Al Ozonoff
Journal:  J Subst Abuse Treat       Date:  2012-09-12

8.  Community-based opioid overdose prevention programs providing naloxone - United States, 2010.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2012-02-17       Impact factor: 17.586

9.  The underrecognized toll of prescription opioid abuse on young children.

Authors:  J Elise Bailey; Elizabeth Campagna; Richard C Dart
Journal:  Ann Emerg Med       Date:  2008-09-06       Impact factor: 5.721

10.  Epidemiology of emergency department visits for opioid overdose: a population-based study.

Authors:  Kohei Hasegawa; David F M Brown; Yusuke Tsugawa; Carlos A Camargo
Journal:  Mayo Clin Proc       Date:  2014-03-11       Impact factor: 7.616

View more
  40 in total

1.  Who receives naloxone from emergency medical services? Characteristics of calls and recent trends.

Authors:  Caroline Geiger; Rosanna Smart; Bradley D Stein
Journal:  Subst Abus       Date:  2019-07-30       Impact factor: 3.716

2.  In Response to: "The Evolution of Recommended Naloxone Dosing for Opioid Overdose by Medical Specialty".

Authors:  Juliana Lombardi; Eric Villeneuve; Sophie Gosselin
Journal:  J Med Toxicol       Date:  2016-10-24

3.  Engaging Law Enforcement in Overdose Reversal Initiatives: Authorization and Liability for Naloxone Administration.

Authors:  Corey S Davis; Derek Carr; Jessica K Southwell; Leo Beletsky
Journal:  Am J Public Health       Date:  2015-06-11       Impact factor: 9.308

4.  Simple minimally-invasive automatic antidote delivery device (A2D2) towards closed-loop reversal of opioid overdose.

Authors:  Bahar Dhowan; Jongcheon Lim; Michael D MacLean; Alycia G Berman; Min Ku Kim; Qi Yang; Jacqueline Linnes; Chi Hwan Lee; Craig J Goergen; Hyowon Lee
Journal:  J Control Release       Date:  2019-05-31       Impact factor: 9.776

5.  Antidote to cannabinoid intoxication: the CB1 receptor inverse agonist, AM251, reverses hypothermic effects of the CB1 receptor agonist, CB-13, in mice.

Authors:  Gareth Pryce; David Baker
Journal:  Br J Pharmacol       Date:  2017-09-20       Impact factor: 8.739

Review 6.  Flumazenil, naloxone and the 'coma cocktail'.

Authors:  Marco L A Sivilotti
Journal:  Br J Clin Pharmacol       Date:  2015-09-21       Impact factor: 4.335

7.  Modifying and Evaluating the Opioid Overdose Knowledge Scale for Prescription Opioids: A Pilot Study of the Rx-OOKS.

Authors:  Jo Ann Shoup; Shane R Mueller; Ingrid A Binswanger; Anna V Williams; John Strang; Jason M Glanz
Journal:  Pain Med       Date:  2020-10-01       Impact factor: 3.750

8.  Reversal and Prevention of the Respiratory-Depressant Effects of Heroin by the Novel μ-Opioid Receptor Antagonist Methocinnamox in Rhesus Monkeys.

Authors:  Lisa R Gerak; David R Maguire; James H Woods; Stephen M Husbands; Alex Disney; Charles P France
Journal:  J Pharmacol Exp Ther       Date:  2018-11-21       Impact factor: 4.030

9.  Awareness and access to naloxone necessary but not sufficient: Examining gaps in the naloxone cascade.

Authors:  Karin Tobin; Catie Clyde; Melissa Davey-Rothwell; Carl Latkin
Journal:  Int J Drug Policy       Date:  2018-07-31

10.  Use and Misuse of Opioids in Maine: Results From Pharmacists, the Prescription Monitoring, and the Diversion Alert Programs.

Authors:  Brian J Piper; Clare E Desrosiers; John W Lipovsky; Matthew A Rodney; Robert P Baker; Kenneth L McCall; Stephanie D Nichols; Sarah L Martin
Journal:  J Stud Alcohol Drugs       Date:  2016-07       Impact factor: 2.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.